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Objectives: The aim of this ﬁrst global systematic review on selected nutraceuticals was to synthesize and
evaluate scientiﬁc relevant data available in the literature. Evidences that can support health, physio-
logical or functional beneﬁt on osteoarthritis (OA) were gathered and the level of evidence relative to
each of these ingredients was highlighted.
Methodology: Relevant scientiﬁc data (positive or not) regarding OA were searched for ﬁve groups of
compounds (avocado/soybean unsaponiﬁables (ASU), n-3 polyunsaturated fatty acids, collagen hydro-
sylates (CHs), vitamin D, polyphenols) within preclinical (in vitro and in vivo), epidemiological, and
clinical studies. The following criteria were evaluated to assess the methodology quality of each study:
(1) study question; (2) study population; (3) primary endpoint; (4) study design (randomization, control,
blinding, duration of follow up); (5) data analysis and interpretation. A scientiﬁc consensus was deter-
mined for all studied nutraceuticals to evaluate their efﬁcacy in OA.
Results: The studied compounds demonstrated different potencies in preclinical studies. Most of them
have demonstrated anti-catabolic and anti-inﬂammatory effects by various inhibitory activities on
different mediators. Vitamin D showed a pro-catabolic effect in vitro and the polyphenol, Genistein, had
only anti-inﬂammatory potency. The evaluation of the clinical data showed that ASU was the only one of
the studied ingredients to present a good evidence of efﬁcacy, but the efﬁcient formulation was
considered as a drug in some countries. Pycnogenol showed moderate evidence of efﬁcacy, and vitamin
D and collagen hydrolysate demonstrated a suggestive evidence of efﬁcacy, whereas curcumin, epi-
gallocatechin-3-gallate (EGCG) and resveratrol had only preclinical evidence of efﬁcacy due to the lack of
clinical data. The literature gathered for n-3 PUFA, nobiletin and genisteinwas insufﬁcient to conclude for
their efﬁcacy in OA.
Conclusion: Additional data are needed for most of the studied nutraceuticals. Studies of good quality are
needed to draw solid conclusions regarding their efﬁcacy but nutraceuticals could represent good
alternates for OA management. Their use should be driven by any recommendations.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is the most prevalent joint disease. It causes
pain and disability in a large proportion of the population world-
wide. It is considered as the most consequential rheumatic condi-
tion in terms of social-economic impacts. The incidence of the
disease increases with age. The disease evolves over decades to endY. Henrotin, Bone and carti-
HU Sart-Tilman, 4000 Liège,
.
s Research Society International. Pby the loss of joint function. In addition, aging patients present
various co-morbid conditions that add to the complexity of the
treatment of OA patients.
To date, there is no cure for OA. The only available treatments
aim at reducing symptoms, as pain and inﬂammation, maintain
joint mobility and limit the loss of function. The main goals that the
ideal OA treatment has to achieve are symptom-modifying effect,
reducing pain and inﬂammation, and structure-modifying effect,
sparing joint structure and preventing joint degradation in order to
maintain articular function.
Several guidelines, as the European League Against Rheumatism
(EULAR), the American College of Rheumatology (ACR) or theublished by Elsevier Ltd. All rights reserved.
Table I
Studied compounds
- n-3 PUFAs
B EPA
B DHA
B ALA
- ASU
- CHs
- Vitamin D
- Polyphenols
Y. Henrotin et al. / Osteoarthritis and Cartilage 19 (2011) 1e212Osteoarthritis Research Society International (OARSI) recommen-
dations for the management of knee OA1e4 have been published for
OA management. They all recommend both non-pharmacological
and pharmacological approaches. The non-pharmacological inter-
ventions include education and self-management, regular tele-
phone contact, referral to a physical therapist, aerobic, muscle
strengthening and water-based exercises, weight reduction,
walking aids, knee braces, footwear and insoles, thermal modali-
ties, transcutaneous electrical nerve stimulation and acupuncture.
The pharmacological treatments consist of acetaminophen, cyclo-
oxygenase-2 (COX-2) non-selective and selective oral non-steroidal
anti-inﬂammatory drugs (NSAIDs), topical NSAIDs and capsaicin,
intra-articular injections of corticosteroids and hyaluronates,
glucosamine and/or chondroitin sulphate, and avocado/soybean
unsaponiﬁables (ASU) for symptom relief; glucosamine sulphate,
chondroitin sulphate and diacerein for possible structure-modi-
fying effects and the use of opioid analgesics for the treatment of
refractory pain1,5. Most of the pharmacological treatments available
to relieve OA symptoms present serious adverse events, as the risk
of gastro-intestinal or cardiovascular adverse events with NSAIDs.
Moreover, this disease implies treatment or drug intake for
decades, increasing the risk of serious adverse events and the
incidence of co-morbidity factors.
Many efforts have been developed to ﬁnd a cure to OA that can
satisfy all the above-mentioned goals. The perfect drug would be
not only able to relieve inﬂammation and pain but also to slow
down, stop or even better prevent disease progression. This would
result in the maintenance of joint function, sparing joint structures
involved in OA, meaning cartilage, synovial membrane and sub-
chondral bone.
From the molecular point of view, OA joints are the site of
inﬂammation and catabolism. Many key mediators have been
identiﬁed in cartilage for both pathways. Inﬂammation is linked to
interleukin (IL)-1b, COX-2 expression and prostaglandin E2 (PGE2)
and nitric oxide (NO) production. Catabolism results from an
imbalance with anabolism. The synthesis of catabolic enzymes as
different matrix metalloproteinases (MMP-1, 3 or -13) or the dis-
integrin and metalloprotease with thrombospondine motifs
(ADAMTS)-4 and -5 (also known as aggrecanases) is increased
resulting in the degradation of the main cartilage matrix compo-
nents (proteoglycan (PG) and type II collagen). In parallel, the
synthesis of the matrix components is decreased. Synovial
inﬂammation is directly linked to cartilage degradation. In addition,
subchondral bone is the site of strong remodeling processes
resulting in bone sclerosis. All these factors produce the loss of the
articular integrity and the loss of joint function.
Indeed, there is a strong necessity for prevention of OA. The ﬁrst
step passes by healthy lifestyle, weight loss and nutrition, with
speciﬁc nutrients that could help to achieve this goal. Nutraceut-
icals are good candidates to help patient preventing OA or
managing their disease using them as treatment adjuvant.
Nutraceutical comes from the combination of the words nutri-
tion and pharmaceutical. It corresponds to food or food product
that provide health and medical beneﬁts, including prevention and
treatment6,7. By deﬁnition and regulatory laws they are devoid of
adverse effects.
Nutraceuticals are good candidates for long-term prevention of
chronic disease, such as OA. Many compounds have already been
studied and a review by Ameye and Chee6 has gathered all the
scientiﬁc data available at that time. There are several emerging
alternatives. It is more and more recognized that nutraceuticals
could help to maintain bone and joint health. However this is
paramount to give a critical point of view to judge the quality of the
studies. Nutraceuticals are under minimal and vague regulation.
Dietary supplements do not have to be approved by the US Foodand Drug Administration (FDA). Nutraceuticals are monitored as
dietary supplement within the US and the deﬁnition for functional
foods varies depending on countries. In Europe the situation is
different with an ongoing regulatory reform tightening the existing
regulatory framework. Indeed, European Food Safety Authority
(EFSA) adopted Regulation 1924/2006 on the use of nutrition and
health claims for food in December 2006. This regulation
harmonised rules across the European Union (EU) for the use of
health or nutritional claims on foodstuffs, which are based on
nutrient proﬁles. One of its key objectives is to ensure that all
claims made on food labels in the EU are “clear and substantiated
by scientiﬁc evidence”. EFSA is responsible for verifying the scien-
tiﬁc substantiation of the submitted claims, some of which are
currently in use, some of which are proposed by applicants. This
information serves as a basis for the European Commission and
Member States, which will decide whether to authorize each
individual product claim. EFSA started to release opinions in
October 2009 on health claims submitted under Article 13 of the
regulation, covering so-called generic health claims.
The aim of this ﬁrst global systematic review on selected
nutraceuticals was to synthesize and evaluate scientiﬁc relevant
data available in the literature. Evidences that can support health,
physiological or functional beneﬁt on OA were gathered and the
level of evidence relative to each of these ingredients was
highlighted.
Methodology
Relevant scientiﬁc data (positive or not) regarding OA were
searched for ﬁve groups of compounds (Table I) within in vitro
(Table III), in vivo (Table IV), epidemiological (Table V), and clinical
studies (Table VI). The selection of compounds discussed in this
paper is arbitrary and was based mainly on the following criteria:
amount of emerging science, safety of use, regulatory constrains
(Novel Food), natural presence in food. The objective was in the end
to identify ingredients that could support joint health, but also that
could be authorized in food and would be relevant to be delivered
through a food matrix.
We have voluntary eliminated glucosamine sulphate, glucos-
amine-HCl, and chondroitin sulphate because these natural
compounds are considered as drugs in some countries, and that
they have been the main topic of numerous systematic review and
meta-analysis5,8e13. The search was performed according to the
following criteria: (1) only scientiﬁc data with a direct link to OA
were selected; (2) only orally administered treatments were
selected for in vivo studies and clinical trials (CTs); (3) only publi-
cations in English were considered (4) only scientiﬁc data allowing
to evaluate the effect of the compound alone were considered.
Articles describing the results of a study previously published were
excluded. The search was performed in Pubmed/Medline database
between January 1990 and 2010.
This search was performed using the combination of terms
related to OA (arthrosis or osteoarthr* OR gonarthro* OR coxarthro*
OR “joint pain” OR “joint comfort” or chondro* or ﬁbroblast* OR
Table II
Results of Pubmed data search performance
Compound Total number of
publications
retrieved
Total number of
publications
selected
Nb of in vitro
studies
Nb of in vivo
studies
Nb of
observational CTs
Nb of
interventional CTs
n-3 PUFAs 1508 9 4 2 1 2
ASU 59 17 9 4 0 4
CHs 51 7 2 1 0 4
Vitamin D 2249 9 3 1 5 0
Pine bark extract 13 4 0 0 0 4
Prodelphinidins 1 1 1 0 0 0
Nobiletin 10 3 3 0 0 0
Genistein 571 3 2 1 0 0
EGCG 81 7 7 0 0 0
Resveratrol 146 6 5 1 0 0
Curcumin 231 12 12 0 0 0
Ventol 2 1 1 0 0 0
Quercetin 210 1 1 0 0 0
Y. Henrotin et al. / Osteoarthritis and Cartilage 19 (2011) 1e21 3synov* OR subchond* OR cartilage OR collagen) and each studied
compound name (or abbreviation).
The methodological quality of each CT supporting functional
ingredient efﬁcacy was determined according to an assessment
model adapted from EFSA and FDA recommendations (EFSA, 2007;
FDA, 2003), AFSSA (“Agence Française de Sécurité Sanitaire des
Aliments”) guidelines (AFSSA, 2007) and other relevant refer-
ences6,14,15 (ANAES “Agence Nationale d’Accréditation et d’Evaluation
en Santé”, 2000). The quality is scored according to a set of 14
criteria. One point is marked for each criterion presented in the
description of the CT. The points are then summed and the ﬁnal
score allow classifying the CT quality in four different categories:
a score below six represents a poor methodological quality, from 7
to 9 represents a medium methodological quality, from 10 to 11
represents a good methodological quality and ﬁnally a score from
12 to 14 represents a very good methodological quality.
A scientiﬁc consensus was reached between the two evaluators
(YH and CL) by considering different points: the total number of CTs
(showing or not a beneﬁcial effect), the quality of these CTs, the
number of epidemiological studies showingor not a relationship, the
heterogeneity in the body of evidence, the presence of preclinical
basis and the presence of ongoing CTs. The studies were then clas-
siﬁed as good evidence of efﬁcacy, moderate evidence of efﬁcacy,
limited evidence of efﬁcacy but suggestive, preclinical evidence of
efﬁcacy, lack of evidence of efﬁcacy, some evidence of inefﬁcacy.
Scientiﬁc consensus for each ingredient is summarized in Table VII.
Furthermore, a search of ongoing CTs (Table VIII) was carried out
on the clinicaltrials.gov database using the term “osteoarthritis” and
each studied compound’s name, in order to complete existing
published data and give an overview of current research interest on
the selected ingredients.
Results
Bibliographic search results
The results of the search performed on Pubmed/Medline data-
base are described in Table II.
N-3 polyunsaturated fatty acids (n-3 PUFAs)
n-3 PUFAs (linolenic acid and eicosapentenoic acid (EPA)) are
essential fatty acids. These compounds are candidate for the
reduction of inﬂammation as they can substitute arachidonic acid
(main precursor of prostaglandins) in the synthetic pathway of
inﬂammatory mediators. The reduction of inﬂammation can also
have an impacton the catabolic pathwaysandby thatwayondisease
progression. They have been widely studied in cardiovascular andinﬂammatory diseases as rheumatoid arthritis16,17. These studies
demonstrated the beneﬁcial effects of a higher n-3 intake. It is
important to note that Western diet is richer in n-6 PUFAs (linoleic
acid and arachidonic acid) rather than in n-3 PUFAs6.
In vitro and preclinical data
n-3 PUFAs have been extensively studied in various cell types,
but only few studies have assessed their anti-inﬂammatory or anti-
OA effects in joint cell models. Three in vitro studies have been
identiﬁed using bovine chondrocytes or human and bovine carti-
lage explants. These studies used n-3 PUFAs alpha-linolenic acid
(ALA), EPA and docohexanoic acid (DHA)18e20. These studies
demonstrated the potency of n-3 PUFAs at reducing inﬂammatory
mediators (IL-1a, COX-2, 5-lipoxygenase (LOX) and its activator
FLAP) and also catabolic factors (MMPs or ADAMTS). Furthermore,
recent published data have also shown that n-3 PUFAs reduced
IL-1b-induced ADAMTS-4, -5, MMP-3, -13 and COX-2 mRNA in
bovine chondrocytes culture21.
Similarly, only one animal study on n-3 PUFAs and OA has been
identiﬁed in the literature22. This study investigated the effect of
n-3 PUFAs on rats with a marginally deﬁcient essential fatty acid
state. n-3 PUFA produced a 70% maximum decrease in the linoleic
and arachidonic acid content of articular cartilage. n-3 PUFA also
produced a 30e40% decrease in the cartilage hexosamine content
and a 32% inhibition of PG synthesis. This is important to keep in
mind that this study demonstrated that a too low n-6/n-3 ratio can
be negative, as a diet with very low n-6 PUFAs intake induced
surface irregularities and PG depletion in cartilage of rats6,22.
Finally, the only one in vivo study testing n-3 PUFAs in client-
owned OA dogs was just published23. The results are in favor of the
beneﬁcial effect of n-3 PUFAs on OA dogs.
Epidemiological data
One observational study was identiﬁed. This study investigated
using Magnetic resonance Imaging (MRI), the association of
different fatty acids consumptionwith cartilage structure and bone
marrow lesions (which have been shown to be associatedwith knee
pain and predictive of cartilage loss in knee OA)24. The main obser-
vation of this study showed that high intakes of monounsaturated,
total and n-6 PUFAs are associated with increased risks of bone
marrowlesions. The resultsmadeno associationbetweenn-3 PUFAs
and either bone marrow lesions or cartilage volume or defects.
Clinical data
The clinical data on n-3 PUFAs are limited. Two studies that
investigated the effect of natural extract or oil with high content of
n-3 PUFAs on OA symptoms were identiﬁed. One study of medium
quality (score: 7)25 showed that a daily intake of 10 ml of cod liver
Table III
Summary of the in vitro effects of the studied products on OA
Reference Product Dose and incubation
duration (ID)
In vitro model Results
n-3 PUFAs
Curtis et al. 200018 EPA, DHA or ALA 10e100 mg/ml
ID: 8 h
Bovine chondrocytes Dose-dependent reducti of IL-1a induced-aggrecanase expression and activity
Reduction of IL-1a, TNF- nd COX-2 (with ALA) expression
Curtis et al. 200219 ALA or EPA 10e100 mg/ml
ID: 24 h
Human OA cartilage explants Reduction of endogenou nd IL-1-induced release of PG
metabolites in a dose-de ndant manner by n-3 PUFA but not by n-6 PUFA
Suppression of the endo ous proteolytic activity of aggrecanase
and collagenase by n-3 P As
Suppression of the mRN xpression of ADAMTS, MMP-3 and
MMP-13 by n-3 PUFA
No effect of n-3 PUFA on MP-1, -2 and -3
Curtis et al. 200220 EPA or ALA 10e300 mg/ml
24 h pre-treatment with EPA or ALA
and 4 days ncubation with IL-1b
Normal bovine or
osteoarthritic human cartilage
explants stimulated with IL-1b
Reduction of IL-1-induce nﬂammation and catabolism
(reduction of GAG releas nd of aggrecanase activity, loss of
COX-2 and 5-LOX expres n) by n-3 PUFA
No effect of n-3 PUFA on rmal tissue homeostasis
Zainal et al. 200921 EPA, DHA or ALA 2.5e30 mg/ml
8 h pre-treatment and 4 days
incubation with IL-1b
Normal bovine articular
chondrocytes stimulated with
IL-1b
Demonstration of the ch drocyte ability to incorporate exogenous PUFAs
Reduction of IL-1b-induc production of cartilage degradating
enzyme (agrecanases, M s) and inﬂammatory cytokines
Inhibition of COX-2 by n PUFAs but not COX-1
ASU
Mauviel et al. 198933 ASU 0.1e10 mg/ml
ID: 24 h and 8e14 days
Synoviocytes
Rabbit articular chondrocytes
No impact of ASU alone collagen synthesis in synoviocytes and
chondrocytes after 24 hI ibition of IL-1b-induced collagen synthesis decrease
in synoviocytes after 24 imulation of collagen synthesis on articular
chondrocytes after 8e14 ys
Mauviel et al. 199134 ASU Piascledine 10 mg/ml
ID: 48 h
Rabbit articular chondrocytes
Human rheumatoid
synovial cells
Slight increase of collage roduction in both cell types
Partial inhibition of IL-1b duced release of collagen in synovial
cells and total suppressi in chondrocytes
Henrotin et al. 199835 ASU mixed in
three ratios
1:2 (A1S2)
2:1 (A2S1)
1:1 (A2S2)
10 mg/ml
ID: 72 h
Human chondrocytes Reduction of the strome in (MMP-3), IL-6, IL-8 and PGE2 spontaneous
productionDecrease of th collagenase activity in unstimulated and stimulated
chondrocytes by A1S2Pa l inhibition of IL-1 effects
Boumediene et al. 199939 ASU 10e25 mg/ml Bovine articular chondrocytes Stimulation of the expre n of TGFb1, TGFb2, plasminogen
activating inhibitor-1 (PA )
Henrotin et al. 200336 ASU (A1S2) 0.625e40 mg/ml
ID: 12 days
Human OA chondrocytes
stimulated or not with IL-1b
Stimulation of aggrecan duction and restoration of aggrecan
production after IL-1b st ulation
Decrease of basal and IL- -stimulated MMP-3 production
Weak inhibition of IL-1b nduced TIMP reduction
Inhibition of basal produ on of MIP-1b, IL-6, IL-8, NO and PGE2
Stimulation of TIMP-1 p uction
Henrotin et al. 2006
(abstract)40
ASU 10 mg/ml
ID: 72 h
Human OA chondrocytes
co-cultured or not with
osteoblasts (obtained from
sclerotic (SC) or non-sclerotic
(NSC) zones of OA
subchondral plate
Prevention of the inhibit effects of SC osteoblasts on matrix
components by pre-trea ent of SC osteoblasts with ASU
Increase of type II collag mRNA level in co-culture with
ASU-pretreated SC osteo sts
No modiﬁcation of MMP IMP-1, TGF-b1, TGF-b3 or iNOS
expression and COX-2 m A levels in chondrocytes when
co-cultured with ASU-pr eated SC osteoblasts
Au et al. 200738 ASU 25 mg/ml
ID: 72 h
Chondrocytes
THP-1 monocytes/macrophages
Reduction of TNF-a, IL-1 OX-2 and iNOS expression in LPS-stimulated
chondrocytes to non-act ted control levels
Reduction of PGE2 produ on and COX-2 and iNOS expression
Reduction of TNF-a in LP timulated monocyte/macrophage
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Lippiello et al. 200832 Sterols extracted from
three ASU preparations
1e10 mg/ml (sterols)
ID: 48 h
Bovine chondrocytes Upregulation of non-collagenous protein and collagen synthesis as well
as of labelled sulphate uptake
Inhibition of IL-1-induced MMP-3 activity, PGE2 synthesis and
sulphate release
Gabay et al. 200837 ASU 10 mg/ml Mouse or human
chondrocytes stimulated
with IL-1b
Cartilage submitted to a
compressive mechanical
stress (MS)
Decrease of MMP-3 and -13 expression and PGE2 synthesis
Inhibition of the degradation of IkBa and suppression of NF-kB translocation
Inhibition of Erk 1/2 but no effect on the other IL-1b-induced MAPK
CH
Oesser and Seifert, 200350 CH 0.5 mg/ml
ID: 48 h
Bovine chondrocytes Dose-dependant increase of type II collagen secretion
No increase in type II collagen secretion by native collagens and
collagen-free hydrosylate of wheat proteins (used as control)
No effect on the expression of proteases
Schunck et al. 200651 CH
Glucosamine
Not provided (NP) Porcine articular chondrocytes
Human femoral head chondrocytes
Increase of PG synthesis, aggrecan expression and type II collagen biosynthesis
with CH
No effect of glucosamine on extracellular matrix macromolecules
(glucosamine sulphate and hydrochloride)
Vitamin D
Tetlow and Woolley, 199966 1,25-dihydroxy-
vitamine D3
108 M
ID: 48 h
Rheumatoid synovial
ﬁbroblasts (RSF)
stimulated or not with IL-1b
Human articular chondrocytes
stimulated or not with IL-1b
No effect on spontaneous MMP and PGE2 production by RSF
Reduction of IL-1b-induced MMP and PGE2 production (up to 50%) by RSF
Slight reduction of spontaneous MMP-1 and -3 production by chondrocytes
No effect on IL-1b-induced MMP and PGE2 production and stimulation of
IL-1b-induced MMP-3 production by chondrocytes
Cantatore et al. 200460 1,25-dihydroxy-
vitamine D3
108 M
ID: 48 h
Osteoblasts from OA subchondral
bone samples
Increased stimulation of osteoclacin production by maximally damaged
Osteoblasts compared to minimally damaged ones
Tetlow and Woolley, 200165 1,25-dihydroxy-
vitamine D3
108 M
ID: 48 h
Human articular chondrocytes
stimulated with TNF-a or
phorbol myristate acetate (PMA)
No effect on MMP-1, -9 and PGE2 production
Upregulation of MMP-3 with or without stimulation with TNF-a or PMA
Polyphenols
Ishiwa et al. 200078 Nobiletin NP
ID: NP
Rabbit synovial ﬁbroblasts
Rabbit articular chondrocytes
Suppression of IL-1-induced MMP-9 mRNA expression and production
Reduction of IL-1-induced PGE2 production
No modiﬁcation of the synthesis of total protein
Imada et al. 200877 Nobiletin 16e24 mM
ID: 24 h
Normal human synovial
ﬁbroblasts
Suppression of IL-1b-induced ADAMTS-4 and -5 mRNA expression
Lin et al. 200379 Nobiletin 6e64 mM
ID: 24 h
Normal human synovial
ﬁbroblasts
Suppression of IL-1b-induced production
of PGE2 in a dose-dependant manner
Selective downregulation of COX-2 but not
COX-1 mRNA expression
Downregulation of IL-1b-induced gene
expression and production of pro-MMP-1
and pro-MMP-3
Increased production of the endogenous
MMP inhibitor, TIMP-1
Williamson et al. 2006
(abstract)86
Resveratrol and/
or Curcumin
2.5 mM
ID: 5 days
LPS-stimulated canine
cartilage explants
Decrease of GAG release by curcumin
alone and in combination with resveratrol
Lev-Ari et al. 200692 Curcumin 0e20 mM
ID: 72 h
OA synovial adherent cells Increased inhibitory effect of celecoxib on COX-2 activity
Stimulation of the growth-inhibitory and anti-apoptotic effects of celecoxib
Schulze-Tanzil et al. 200482 Curcumin 50 mM
ID: 12e48 h
Human chondrocytes
stimulated with IL-1b
Prevention of IL-1b-induced MMP-3 upregulation
Inhibition of IL-1b-induced-type II collagen synthesis suppression
Prevention of NF-kB translocation
Shakibaei et al. 200584 Curcumin 50 mM
ID: 5e30 min
Human articular chondrocytes Anti-apoptotic and anti-catabolic effects on IL-1b-stimulated chondrocytes
(continued on next page)
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Table III (continued)
Reference Product Dose and incubation
duration (ID)
In vitro model Results
Liacini et al. 200381 Curcumin 10e15 mM
ID: 24 h
Human OA chondrocytes Inhibition of TNF-a-induced MMP-13 gene expression
Shakibaei et al. 200783 Curcumin 50 mM
ID: 72 h
Human articular chondrocytes
stimulated with IL-1b
Suppression of NF-kB mediated IL-1b or TNF-a catabolic signalling pathways
resulting in COX-2 and MMP-9 downregulation and type II collagen upregulation
Toegel et al. 200885 Curcumin 5e50 mM
ID: 24e48 h
Immortalized human chondrocytes
(C-28/I2) stimulated with IL-1b
No effect on aggrecan and type I and II collagen gene expression, proliferation
and morphology at low concentrations
Cell damages at high concentrations (reduction of cell viability)
Increase of type II collagen, MMP-3 and ADAMTS-4
expression and decrease of type I collagen expression with high concentrations
Clutterbuck et al. 2008 (abstract)89 Curcumin 25e100 mM
ID: 5 days
Equine cartilage explants
stimulated with IL-1b
Reduction of IL-1b-induced GAG release (50e100 mM)
Decrease of PGE2 release (25e100 mM)
Clutterbuck et al. 200987 Curcumin 0.1e100 mM
ID: 5 days
Equine cartilage explants
stimulated with IL-1b
Suppression of IL-1b-induced GAG release
Mathy et al. 2007 (abstract)88 Curcumin 1e30 mM
ID: 24 h
Primary bovine chondrocytes
stimulated with IL-1b
No effect on cell viability
Dose-dependant inhibition of IL-1b-induced COX-2, iNOS, IL-6 and IL-8 gene
expression, PGE2 and NO production
Chowdhury et al. 200891 Curcumin 0.01e1000 ng/ml
ID: 48 h
Bovine chondrocytes cultured
in agarose
Inhibition of IL-1b-induced NO and PGE2 release
Inhibition of 35SO4 incorporation
Mathy-Hartert et al. 200990 Curcumin 5e20 mM
ID: 12 days
Human articular chondrocytes
in alginate beads and
human cartilage explants
stimulated with IL-1b
No effect on cell viability
Dose-dependent reduction of the synthesis of inﬂammatory mediators
(NO, PGE2, IL-6, IL-8) and catabolic factor (MMP-3)
Claassen et al. 200894 Genistein 1011e104 M
ID: 24 h
(for incubation or
preincubation)
Foetal bovine articular chondrocytes No effect on GAG release within the physiological range of concentrations
Decrease of GAG release with high doses (105e104 M)
No effect on sulphate incorporation by chondrocytes
Preincubation with 109e105 M enhanced the stimulatory effect of insulin
on sulphate incorporation by chondrocytes
Hooshmand et al. 200795 Genistein 50e100 mM
ID: 1 h
preincubationþ24 h
Human chondrocytes stimulated
by LPS
Reduction of pro-inﬂammatory molecules (COX-2 and NO)
No effect of YKL-40 (marker of cartilage metabolism) or IL-1b levels
Singh et al. 200298 EGCG 1e100 mM
ID: 30 min
preincubationþ24 h
Human OA chondrocytes
stimulated with IL-1b
Inhibition of IL-1b-induced NO production by interfering with NF-kB activation
Ahmed et al. 200297 EGCG 100e200 mM
ID: 2 h
preincubationþ24 h
or 24 h without
preincubation
Human OA chondrocytes
stimulated with IL-1b
Dose-dependant inhibition of NO and PGE2, iNOS and COX-2 expression
Singh et al. 200399 EGCG 5e200 mM
ID: 24e48 h
Human OA chondrocytes stimulated
with IL-1b
Suppression of IL-1b-induced upregulation of catabolic mediators dependant
on the activation of c-jun N-terminal kinase (JNK) activation
Rasheed et al. 2009102 EGCG 25-200 mM
ID: 1e2 h pre-treatment
with EGCGþ4 days treatment
with AGE
Human OA chondrocytes stimulated
with AGE
Inhibition of AGE-induced expression of TNF-a and MMP-13
Attenuation of the AGE-induced MAP kinase signalling pathways
Inhibition of NF-kB activation
Ahmed et al. 2004 103 EGCG 1e200 mM
ID: 72 h
Human cartilage explants and
chondrocytes
Inhibition of IL-1b-induced GAG release from human cartilage explants
Dose-dependant inhibition of MMP-1 and MMP-13 IL-1b-induced mRNA and
protein expression in human chondrocytes
Dose-dependant inhibition of transcription activity of NF-kB and AP-1
Tokuda et al. 2008 (abstract)100 EGCG NP Osteoblast-like MC3T3-E1 cells Inhibition of the ﬁbroblast growth factor (FGF)-2-stimulated synthesis of IL-6
at least in part through the suppression of p44/p42 and the p38
Map kinase pathways
Huang et al. 2009101 EGCG 10e50 mM
ID: 12 h
Human synovial ﬁbroblasts stimulated
with IL-1b
Inhibition of IL-1b-induced COX-2 expression and synthesis
Inhibition of IL-1b-induced PGE2 and IL-8 secretion
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Williamson et al. 2006 (abstract)86 Resveratrol and/or
Curcumin
2.5 mM
ID: 5 days
Canine cartilage explants stimulated
with LPS
Decrease of GAG release by resveratrol alone
Inhibition of the degradative effects of LPS and decrease of GAG release by
co-treatment with resveratrol and curcumin
Dave et al. 2008105 Resveratrol 1e10 mM
ID: 1 h pre-treatment
Human OA chondrocytes and
cartilage explants stimulated
by IL-1b
Inhibition of IL-1b-induced and spontaneous of PGE2 and LTB4 production,
and suppression of COX-2 expression
Spontaneous stimulation of PG and inhibition of pro-MMP-13
Prevention of OA cartilage degradation from IL-1b-induced effects
Prevention of chondrocytes apoptosis
Csaki et al. 2008106 Resveratrol 1e200 mM
ID: 1e24 h
Human articular chondrocytes
stimulated by IL-1b
Chondroprotective effect through suppression of IL-b-, reactive oxygen species
(ROS)- and tumor suppressor protein p53-production
Shakibaei et al. 2008107 Resveratrol 100 mM
ID: 4 h (pre-
treatmentþ 1e32 h
(in combination
with IL-1b)
Human articular chondrocytes
stimulated by IL-1b
Inhibition of IL-1b-induced vascular endothelial growth factor (VEGF), MMP-3,
MMP-9 and COX-2
Suppression of apoptosis and inﬂammatory signalling by acting on NF-kB
Lei et al. 2008108 Resveratrol 100 mM
ID: 24 h
Rat bone marrow mesenchymal
stem cells derived chondrocytes
stimulated by IL-1b and cultures
on chitosan-gelatine
scaffolds (CGS)
Inhibition of IL-1b-induced downregulation of type II collagen and aggrecan
and increased of MMP-13 expression by reducing the translocation of NF-kB
Spontaneous decrease of type II collagen but no effect on aggrecan and
MMP-13 expression
Garbacki et al. 2002111 Prodelphidins isolated
from Ribes nigrum
Gallocathechin trimer
(CG-CG-CG), dimer
(CG-CG) or monomer
(CG-ECG)
1e100 mg/ml
ID: 5 mine12 days
Human chondrocytes Stimulation of PG and type II collagen production by all tested prodelphidins
Decreased of PGE2 synthesis by all prodelphidins
Inhibition of COX-2 but not COX-1 by all prodelphidins
Sato et al. 1997 (abstract)112 Quercetin NP Human synovial cells Suppression of TNF-a mediated stimulation of IL-8 and MCP-1 expression,
at least in part by inhibiting NF-kB activation
Kang et al. 2004 (abstract)113 Ventol NP Cartilage explants Inhibition of IL-1b-induced PG degradation
IkB: inhibitor of NF-kB.
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Table IV
Summary of the in vivo effects of the studied products on OA
Reference Product Dose and ID In vivo model Results
n-3 PUFAs
Lippiello et al., 1990 (abstract)22 n-3 PUFA
(menhaden ﬁsh oil)
Diet with 10% menhaden ﬁsh oil
ID: NP
Male SpragueeDawley with a “marginally
deﬁcient” essential fatty acid state
70% maximum decrease in articular cartilage content of the
linoleic and arachidonic acid in the ﬁsh oil treated group
30e40% decrease in cartilage hexosamine content and 32%
inhibition of PG synthesis
Roush et al., 201023 n-3 PUFA Diet with 31-fold increase of the
total omego-3 fatty acids
ID: 24 weeks
Client-owned dogs with OA
N¼ 127
Signiﬁcant improvement of dog conditions
ASU
Cake et al., 200028 ASU 900 mg/weekday vs placebo
ID: 6 months
Ovine model of knee OA (bilateral lateral
meniscectomy)
N¼ 32
Reduction of subchondral bone sclerosis and increase of PG
content and of articular knee joint thickness
Altinel et al., 200742 ASU 300 mg every day or every 3 days
ID: 3 months
Sheepdogs
Control: normal diet
N¼ 24
Increase of both TGF-b1 and TGF-b2 levels in knee joint ﬂuid
Kawcak et al., 2007 41 ASU (A1:S2) NP
ID: 70 days
Experimentally induced OA in horses
N¼ 16
No effect on pain and lameness
Reduction of the severity of cartilage erosion and synovial
haemorrhage
Increase of articular cartilage GAG synthesis
Boileau et al., 200929 ASU 10 mg/kg/day
ID: 8 weeks
Experimental knee dog model Decrease of the size of the macroscopic lesions (tibial
plateaus) compared to control
Decrease in the severity of cartilage lesions (tibial plateaus
and femoral condyles)
Decrease in the scores of all histological parameters
(structural changes, cellularity, Safranin-O staining and
pannus invasion on the femoral condyles)
No difference on the tibial plateaus for Safranin-O and
pannus invasion
Reduction of iNOS production in cartilage
Reduction of the total histological changes and cellular
inﬁltration in synovium
CH
Oesser et al., 2008 (abstract)52 CH (Fortigel, Gelita AG) 0.15 mg/g of body weight daily
ID: 4 months
Male STR/ort (model of naturally occurring OA)
Control: albumin
Decrease of cartilage tissue degeneration in knee joints
Decrease of the incidence of severe joint degradation and in
the determinate grade of OA in comparison to the untreated
control
Vitamin D
Jefferies et al., 200267 25-hydroxyvitamin D3
supplement
0.1 mg/kg/day
ID: 21 weeks
Pigs
N¼ 200
Control: commercial diet
No effect on the incidence or severity of OA lesions, articular
PG or collagen contents
Polyphenols
Ham et al., 200496 Genistein
Soy phytoestrogen
Equivalent of 129 mg/day
for women
ID: 3 years
Monkey model of naturally occurring OA
after ovariectomy
No effect on insulin-like growth factor binding protein
(IGFBP)-2 and IGFBP-3, total protein, PG or collagen levels in
cartilage tissue
Elmali et al., 2005110 Resveratrol 10 mmol/kg
Intra-articular
Rabbit model of OA by transaction of the
anterior cruciate ligament
Protection against cartilage degradation (histological
evaluation)
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Table V
Summary of the epidemiological data for the studied products on OA
Reference Product Population Design Results
n-3 PUFAs
Wang et al., 200824 Different types of
fatty acid
Australian healthy
middle-aged subjects
without clinical knee OA
Mean y: 58
N¼ 297
Cohort
Y: 10
Higher intakes of monounsaturated fatty
acids, total and n-6 PUFAs associated with
increased risk of bone marrow lesions
No association of n-3 PUFA intake and
bone marrow lesions
No association of fatty acid intake
with cartilage volume of defects
Vitamin D
McAlindon et al., 199658 Vitamin dietary intake
and serum levels of 25-
hydroxyvitamin D
English patients
Mean y: 70.3
N¼ 556
Cohort
Y: 9e10
Modest correlation between serum
vitamin D and vitamin D intake
Increased risk of knee OA progression
(global score including joint space
narrowing, osteophytosis and sclerosis)
for low levels of vitamin D and
vitamin D intake
Association between low vitamin D serum
levels and knee loss of cartilage as assessed
by joint space and osteophyte growth
(disease progression)
No association between vitamin D intake
and serum level of vitamin D and
knee OA incidence
Lane et al., 199968 Serum levels of 25-
hydroxyvitamin D
and 1,25-
dihydroxyvitamin D
American elderly white
women
Y 65
N¼ 237
Cohort
Y: 8
Association between low serum levels
of 25-hydroxyvitamin D and radiographic
changes for hip OA characterized by
joint space narrowing but not osteophyte
No association between serum 1,25-
dihydroxyvitamin D and incident
changes of radiographic hip OA
Felson et al., 200769 Serum levels of 25-
hydroxyvitamin D
English adults
Mean y: 53.1
N¼ 715
Cohort Y: 9 No association between vitamin D
levels and structural joint degradation
(disease incidence) deﬁned as joint
space loss on radiography
Felson et al., 200769 Serum level of 25-
hydroxyvitamin D
American adults with
knee OA
Mean y: 66.2
N¼ 388
Cohort Y: 9 No association between vitamin D
levels and structural disease worsening
(disease progression) deﬁned as joint space
loss on radiography and as cartilage loss on MRI
Breijawi et al., 200964 Serum levels of 25-
hydroxyvitamin D
Patients undergoing
total hip or knee
replacement
Mean y: 69e70
N¼ 117
Cross-section High prevalence of low vitamin D status in
patients with knee OA
Bergink et al., 200963 Serum levels of 25-
hydroxyvitamin D
Knee OA patients
N¼ 1248
Cohort Y: 6.5
(mean follow up time)
Low dietary vitamin D intake the risk of
progression of knee OA
Vitamin D inﬂuences the incidence and
progression of knee OA more particularly
in low BMD patients
Y. Henrotin et al. / Osteoarthritis and Cartilage 19 (2011) 1e21 9oil (equivalent to 786 mg EPA) by OA patients as an adjunct to
NSAIDmedicationwas not effective to improve pain and ability. The
use of olive oil as placebo control may have introduced a bias in the
result of this study. On the contrary, the second study of low
methodological quality (score: 4)26 showed that the consumption
of an extract of New-Zealand green-lippedmussel rich in n-3 PUFAs
improved OA symptoms, including pain and joint function in
Korean OA patients.
ASU
ASU are derived from unsaponiﬁable residues of avocado and
soybean oils, generally mixed in the ratio one-thirdetwo-thirds
respectively27e30. The large majority of the in vitro and in vivo
data have been obtained with ASU found in Piascledine300
(Laboratoires Expanscience, France). The ASU contained in
Piascledine300 are extracted according to a patented process
giving them a particular formulation30. This formulation is
considered as a drug in France and some of the observed beneﬁcial
effects seem to be related to this particular formulation. In othercountries, ASU mixtures are delivered as over-the-counter prod-
ucts. Therefore, extrapolation of the data obtained with
Piascledine300 to other ASU mixtures must be done with an
extreme caution. The main components of ASU are the phytosterols
b-sitosterol, campesterol and stigmasterol31.
In vitro and preclinical data
Over the last 20 years, ASU have raised a great research interest.
In vitro data are abundant. Most of in vitro studies were performed
with normal or OA chondrocytes stimulated or not with IL-1b, the
key pro-inﬂammatory cytokine in OA physiopathology. These
studies demonstrated that ASU contained in Piascledine300
exerted positive effects on human chondrocytes by stimulating the
synthesis of aggrecan and extracellular matrix component as type II
collagen31e33 and by reducing the production of catabolic (MMP-3)
and pro-inﬂammatory (IL-8 and IL-6) mediators34. These anabolic
and anti-catabolic effects were also observed in human OA
chondrocytes35. What is more, this ASU mixture was able to
counteract IL-1b-induced deleterious effects on cartilage in normal
and OA chondrocytes31e36. It reversed IL-1b-induced collagen
Table VI
Summary of the clinical data of the studied products on OA
Reference Product Dose and intervention
duration (ID)
Population Design Results Score
(1e14)
n-3 PUFAs
Stammers
et al.,
199225
Cod liver oil
(EPA)
10 ml (786 mg EPA)/
dayID: 24 weeks
English middle-ages and
old patients with OA
Y: 49e87
N¼ 86
Double-blind, placebo-
controlled trial
No effect on pain and ability compared to olive
oil
(Cod liver oil was used as an adjunct to NSAIDs)
7
Cho et al.,
200326
Lyprinol extract from
New-Zealand green-
lipped mussel rich in
n-3 PUFAs (EDA, DHA, DPA)
four capsules/day
ID: 8 weeks
Korean patients with hip or
knee OA
Y: 40e75
N¼ 60
Multicenter open trial Improvement of OA signs and symptoms (pain
VAS, joint function LFI)
4
ASU
Lequesne
et al.,
200243
Piascledine 300 mg (capsule)
ID: 2 years
French patients with
regular pain due to primary
hip OA
Y: 50e80
N¼ 108
Prospective, multicenter,
randomized, parallel group,
double-blind, placebo-
controlled trial
No structural effect (joint space width) (primary
outcome)
Reduction of the progression of joint space loss
in the subgroup with advanced space
narrowing (post-hoc analysis)
No difference for clinical parameters (secondary
outcomes) between ASU and placebo groups
(LFI, global pain on VAS, NSAID use and patient’s
global assessment) over the ﬁrst year follow up
11.5
Appelboom
et al.,
200144
Piascledine 300 or 600 mg
ID: 3 months
Belgian patients with
primary knee OA under
analgesics and/or NSAIDs
Y:45e80
Prospective multicenter,
double-blind, randomized,
parallel group, placebo-
controlled trial
Decrease of NSAID and analgesic intake
(primary outcome), compared to placebo from
the ﬁrst month
No difference between 300 mg and 600 mg
Decrease of LFI (improvement noticed from the
second month) and pain by VAS
11
Maheu
et al.,
199845
Piascledine 300 mg (capsule)
ID: 6 monthsþ 2 month
post)treatment follow up
French patients with
symptomatic primary hip
or knee OA
Y: 45e75
N¼ 164
Prospective, randomized,
double-blind, placebo-
controlled multicenter trial
Decrease of LFI scores (primary outcome) after 6
months, compared to baseline and placebo
groups
Reduction of pain by VAS, overall functional
disability and patient’s overall assessment
efﬁcacy
More important improvement in hip OA
patients
No difference in NSAID consumption except for
the period ranging from 6 to 8 months
Beneﬁcial effects measured by LFI, pain by VAS
and functional disability started after 2 months
(delayed action)
Prolonged effect of ASU, persisting 2 months
after treatment discontinuation
14
Blotman et
al., 1997
(abstract)46
Piascledine 300 mg
ID: 3 months
French patients with
symptomatic knee or hip
OA requiring NSAID
therapy
Mean y: 62.9
N¼ 163
Prospective, randomized,
double-blind, placebo-
controlled, parallel-group
trial
Reduction of NSAID consumption
(primary outcome)
Improvement of LFI compared to placebo
No difference in pain score between ASU and
placebo
CH
Clark et al.,
200854
CH
(liquid formulation)
10 g/day
ID: 24 weeks
American physically active
healthy adults without
degenerative joint disease
but with joint pain
Mean y: 20.1
N¼ 97
Prospective, randomized-
placebo-controlled, double-
blind trial
Control: xanthan
Improvement of joint pain, increase of mobility
and reduction of dependency to analgesics in
patients consuming CH dietary supplement
8
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Moskowitz
et al.,
200056
CH 10 g/day
ID: 24 weeksþ 8 weeks
post-treatment washout
Patients with knee OA
(Germany, UK, US)
Y: 45e81
N¼ 389
Multicenter, prospective,
randomized, double-blind,
placebo-controlled trial
No statistically signiﬁcant improvement in
Western Ontario and McMaster Universities
(WOMAC) pain score, function score and patient
global assessment for the total study group
Pain reduction and functional improvement in
German patients but not in global patient
evaluation
Tendency to be more effective in severe OA
(post-hoc analysis)
9
Zuckley
et al.,
200455
CH 10 g/day with calcium
(300 mg/day) and
vitamin C (60 mg/day)
ID: 14 weeks
Patients with symptoms
of mild knee OAMean
y: 57N¼ 190
Randomized, double-blind,
placebo-controlled trial
Improvement of certain strength and work
performance tests (improvement of knee
functional mobility on isometric and isokinetic
testings)
Greater effects on patients with more severe OA
Benito-Ruiz
et al.,
200957
CH 10 g/day
ID: 6 months
Patients with primary OA
Mean y: 59
N¼ 250
Randomized, double-blind,
multicenter controlled trial
Improvement of knee joint comfort as assessed
by VAS and WOMAC
13
Polyphenols
Belcaro et
al, 200875
Pycnogenol NP
ID: 3 months
OA patients with elevated
C-reactive protein and
plasma-free radicals
N¼ 35
Placebo-controlled trial Decrease of plasma-free radicals compared to
baseline
Decrease of plasma C-reactive protein level
compared to baseline and placebo group
Decrease of ﬁbrinogen level compared to
baseline
No difference for plasma-free radicals, C-
reactive protein and ﬁbrinogen in placebo
group
Decrease of systemic inﬂammatory markers
Cisar et al,
200872
Pycnogenol 150 mg/day
ID: 3 months
Slovakian patients with
mild to moderate OA
Y: 25e65
N¼ 100
Prospective, double-blind,
placebo-controlled, single
centre study
Improvement of WOMAC index (pain, stiffness
and global score compared to both baseline and
placebo group, physical function compared to
baseline only) and alleviation of pain by VAS
compared to placebo
Diminution of analgesic use compared to
baseline and increase use in placebo group
13
Belcaro et
al, 200876
Pycnogenol 100 mg/day
ID: 3 months
Patients with knee OA and
disability Mean y: 47.6
e48.6
N¼ 156
Double-blind, placebo-
controlled randomized trial
Improvement of WOMAC index (pain, stiffness,
physical function and global scores), well-being
of patients and social functions compared to the
beginning and to placebo group
Increase of patient performance
Decrease of oedema
Decrease of analgesic (NSAID) medication
compared to the beginning and to placebo
group
11
Farid et al,
200774
Pycnogenol 150 mg/day
ID: 3 months
Patients with knee OA
Y: 25e65
N¼ 37
Double-blind, placebo-
controlled randomized trial
with parallel-group design
Improvement of WOMAC index (pain, physical
function and global score but not stiffness) from
second month compared to baseline and
placebo
Reduced use of medication (NSAID and COX-2
inhibitor) compared to placebo
11
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Table VII
Summary of scientiﬁc consensus on the reviewed ingredients
Ingredient Scientiﬁc consensus
n-3 PUFA Lack of evidence of efﬁcacy
ASU Good evidence of efﬁcacy
CH Limited evidence of efﬁcacy but suggestive
Vitamin D Limited evidence of efﬁcacy but suggestive
Nobiletin Lack of evidence of efﬁcacy
Curcumin Preclinical evidence of efﬁcacy
Genistein Lack of evidence of efﬁcacy
EGCG Preclinical evidence of efﬁcacy
Resveratrol Preclinical evidence of efﬁcacy
Pycnogenol Moderate evidence of efﬁcacy
Probiotics Lack of evidence of efﬁcacy
Y. Henrotin et al. / Osteoarthritis and Cartilage 19 (2011) 1e2112release, MMP-3, MMP-13, and PGE2 production in normal chon-
drocytes31,33,34,36. It was also shown that ASU mixture contained in
Piascledine300 restored aggrecan production and inhibited MMP-
3 synthesis in OA chondrocytes stimulated with IL-1b35. Other ASUTable VIII
Summary of the ongoing CTs for the studied products on OA
Product Population Design
ASU
(Piascledin 300)
Patients with hip OA
Age: 45e75 years
Enrollement: NP
Multicenter, randomized,
double-blind, placebo-
controlled trial
Duration: 3 years
Treatment: Piascledine
300
CH solution
10 g/day
Patients with knee OA
Age: 49e90 years
Enrollement: 30
Treatment, randomized,
double-blind
(subject, caregiver, investigator,
outcome assessors),
placebo-controlled,
parallel assignment,
safety-efﬁcacy study
Vitamin D
(cholecalciferol)
2 000 UI/day
(capsule)
Patients with
symptomatic knee OA
Age: 45e90 years
Enrollement: 146
Treatment, randomized,
double-blind
(subject, caregiver, investigator,
outcomes assessor), parallel
assignment, efﬁcacy study
Duration: 2 years
Treatments: vitamin D3
2 000 UI daily or placebo
Vitamin D
(cholecalciferol)
2 000 UI/day
(capsule)
Patients undergoing
uni-lateral total knee
replacement
due to sever OA
Age: 60 years
Enrollement: 80
Treatment, randomized,
double-blind
(subject, caregiver, investigator,
outcomes assessor),
dose comparison,
parallel assignment, efﬁcacy study
Duration: 2 years
Treatments: vitamin D3
2 000 UI or 800 UI daily
Curcuma domestica
1 500 mg/day (oral)
divided into 3 times
for 28 days
Patients with knee OA
Age: 50e75 years
Enrollement: 396
Treatment, randomized,
double-blind
(subject, outcomes assessor),
active control,
parallel assignment,
safety/efﬁcacy study
Duration: 28 days
Treatments: curcuma domestica or
ibuprofen (1 200 mg/day)
Highly bioavailable
turmeric extract
(Arantal)
four capsules/day
Patients with knee OA
Age: 40e80 years
Enrollement: 280
Treatment, randomized, placebo-
controlled, double-blind, parallel
assignment, efﬁcacy/tolerance study
Duration: 15 days
Treatment: turmeric extract
(Arantal) or placeboformulations produced similar effect on IL-1b, COX-2 and iNOS in
LPS-stimulated chondrocytes37 and were also shown to enhance
transforming growth factor (TGF)-b production in bovine articular
chondrocytes38. The ASU contained in Piascledine300 were also
shown to have beneﬁcial effects on osteoblasts and synoviocytes.
Indeed, this compound prevented inhibitory effect of osteoblasts on
chondrocyte matrix component synthesis39 and reversed IL-1b-
induced collagenase production by synoviocytes33.
Four in vivo studies with ASU were identiﬁed. They were per-
formed in four different animal models of OA and they all support
the beneﬁcial effect of Piascledine300 in OA. Piascledine300
treatment prevents cartilage degradation (decrease in cartilage
lesion severity, increase in cartilage thickness) by stimulating
matrix component production as glycosaminoglycans (GAG) and
PGs content in experimental models27,28,40. In addition, one in vivo
study in dogs without any diagnosed joint disease suggests an
effect of ASU by increasing growth factors (TGF-b1 and 2) involved
in extracellular matrix synthesis41. All these preclinical studies
strongly support anti-OA properties for ASU mixtures.Primary outcome measure Sponsor Stage
Effect of treatment on joint
space narrowing
evaluated on X-ray
Laboratoires Expanscience Completed
Effect of collagen hydrolysis
on knee cartilage measured
by MRI
GELITA Completed
Cartilage volume loss (MRI)
Knee symptoms (WOMAC)
National Institute of Arthritis
and Musculoskeletal and Skin
Diseases (NIAMS)
Ofﬁce of Dietary Supplement
(ODS)
Ongoing,
not
recruiting
Pain and function of the
operated and non-operated
knee
Rate of falls
University of Zurich
Harvard School of Public
Health
Tufts University
Boston University
Recruiting
Change in mean WOMAC
pain scale
Mahidol University
National research Council of
Thailand
Not yet
open for
patient
recruitment
Pain assessment using VAS Bioxtract S.A.
NuKleus
Recruiting
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The results of four CTs, all double-blind placebo-controlled and
randomized, were published and identiﬁed in the literature.
All of these studies used the same pharmaceutical product,
Piascledine300, which is under drug authorization (AMM). All of
them investigated the beneﬁcial effects of Piascledine300 on
patients with symptomatic OA. All of them were conducted in
patients with primary knee or hip OA and were by the way focusing
on OA treatment. OA outcomes were NSAID/analgesics medication
replacement, pain, function and structural changes (joint space nar-
rowing). They studied the potential of symptom-modifying effect of
Piascledine300 and one of them was interested in the structure-
modifying effect of ASU. Three out of the four evaluated studies were
of good methodological quality (Lequesne et al, 200242, score: 11.5;
Appelboom et al, 200143, score: 11; Maheu et al, 199844, score: 14).
The only one study assessing efﬁcacy of Piascledine300 in
modifying articular structure failed to show any structural effect in
patientswithhipOA in spite of its longduration (2 years)42. However,
a subgroup analysis suggested an effect in patients with the most
severe hip OA, supporting further studies in this population group.
Data suggested that Piascledine300 decreased NSAID/anal-
gesic intake in the medium term (3e6 months) for patients with
hip or knee OA43e45. However, the only long-term study (2 years)
did not show any effect of Piascledine300 on the NSAID
consumption in patients with hip OA42. Nevertheless, the later was
designed to detect radiographic changes more than to study the
changes in symptoms. This could explain the fact that no difference
was observed on clinical parameters (function, pain and NSAIDs
consumption). In contrast, data regarding pain and patient’s global
assessment are more conﬂicting42e45. Piascledine300 treatment
seemed to improve patient’s function assessed by LFI (Lequesne
Functional Index) or VAS (Visual Analog Scale)43e45.
A recent meta-analysis evaluating these four clinical studies
concluded Piascledine300 was efﬁcient for reducing pain and
improving function in OA46.
Collagen hydrosylates (CHs)
CH is obtained by the enzymatic hydrolysis of collagenous
tissues (bone, hide or hide split) form mammals. The main char-
acteristic of CH is its amino acid composition, which is identical to
type II collagen, thus providing high levels of glycine and proline,
two amino acids essential for the stability and regeneration of
cartilage47. This product is generally recognized as a safe food
ingredient by regulatory agencies. CH is well digested and is pref-
erentially accumulated in cartilage48. Although clinical use of CH is
associated with minimal adverse effects, some gastro-intestinal
side effects, as fullness and unpleasant taste, have been described.
In most studies, CH was administered alone in a water solution.
However, it seems that CH is well absorbed and digested in other
food matrix, such as fermented milk47.
In vitro and preclinical data
Few preclinical data on the effect of CH on OAwere identiﬁed in
the literature. The search retrieved only one in vitro study assessing
the stimulation of articular cartilage matrix by CH in cultured
bovine chondrocytes49. This study demonstrated the stimulatory
potency of CH on type II collagen and PG synthesis, as well as
aggrecan expression by chondrocytes. This result was also reported
in a scientiﬁc communication on CH effect in porcine chon-
drocytes50. In addition, an in vivo study with STR/ort mice which
spontaneously developed OA51 has shown that long-term CH
supplementation may decrease OA cartilage degeneration and
delay the progression of OA. These results are in favor of a disease-
modifying effect of CH and its potential efﬁcacy in OA. Thechondroprotective effect of CH was also conﬁrmed in an other
study investigating both in vitro and in vivo effect in mice52. CH was
demonstrated to protect cartilage against degradation induced by
phosphorus injection. The same study showed that CH prevented
chondrocyte differentiation into mineralized chondrocytes.
Clinical data
Only three relevant CTs were identiﬁed in the literature. The ﬁrst
study investigated the effect of CH supplementation in healthy
adult without degenerative joint disease but with joint pain. This
study of medium methodological quality (score: 8)53 showed that
CH dietary supplement can improve joint pain, mobility and reduce
analgesic medication in healthy active adults without degenerative
joint disease. The CH supplementation can then improve knee
function during joint-stressing activities. These observations were
also reported in a scientiﬁc communication54 in patients with
symptomatic mild OA patients. The second report of medium
methodological quality (score: 9)55 mentioned a better effect of CH
compared to placebo in severe OA patients than in the overall
studied population. More recently, in another relevant CT of very
good methodological quality (score: 13), the joint function
improvement after CH treatment was shown in patients with
primary OA56.
Vitamin D
OA was traditionally considered as a cartilage disease, charac-
terized by cartilage degeneration. But many evidences, as osteo-
phytosis, subchondral bone sclerosis and cyst formation have
grown up and demonstrated the prominent role played by sub-
chondral bone in OA pathophysiology57. Some studies even indicate
that bone alteration could precede cartilage changes58. But whether
bone abnormalities, such as bone sclerosis, initiate or are simply
involved in the progression of cartilage degradation is under
discussion59e61.
Normal bonemetabolism depends on the presence of vitamin D,
a compound derived mostly from cutaneous exposure to ultraviolet
and from the diet in a lesser extent. Suboptimal levels of vitamin D
may have adverse effects on calcium metabolism, osteoblastic
activity, matrix ossiﬁcation and bone density. Low serum levels of
vitamin D may increase the progression of knee OA62 and may
impair the ability of bone to respond optimally to OA pathophysi-
ologic processes and may predispose patients to joint degrada-
tion57. High prevalence of low vitamin D status has been
demonstrated in persons with knee OA63. Moreover, in low bone
mineral density (BMD) patient, the level of vitamin D seemed to
inﬂuence the incidence and progression of the disease62. Some
studies have consequently investigated the relationship between
vitamin D and OA. The main drawback is that they are all obser-
vational. Most of them have looked at the association of vitamin D
serum level rather than vitamin D intake with OA.
In vitro and preclinical data
Three in vitro studies investigating the role of 1,25-dihydroxy-
vitamin D3 in the pathophysiology of OA are available59,64,65. These
studies used different cell models: synovial ﬁbroblasts, chon-
drocytes or osteoblasts. Data showed that 1,25-dihydroxyvitamin
D3 had no inhibitory effect on articular catabolic enzymes and on
a potent pro-inﬂammatory mediators but rather upregulated
catabolic enzymes (MMP-1 and -3) in human articular chon-
drocytes64, 65. Interestingly, 1,25-dihydroxyvitamin D3 exerts
a positive effect on rheumatoid synovial ﬁbroblasts by reducing
MMP and PGE2 production65. In addition, 1,25-dihydroxyvitamin
D3-induced osteocalcin production appears to be increased in OA
osteoblasts compared to healthy one, which can cause an increase
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Only one in vivo study was identiﬁed. This study evaluated the
impact of a supplementation of vitamin D3 (25-hydroxyvitamin
D3) on OA in pigs66. The supplementation revealed no effect on the
incidence or the severity of OA lesions, articular PG and collagen
content.
Clinical data
Themajority of available evidence on the efﬁcacy of vitamin D in
the treatment or in the prevention of OA comes from epidemio-
logical data. Most of them investigated the relationship between
vitamin D serum levels and joint structure parameters (joint space
narrowing, osteophytes, cartilage loss and volume). A total of four
studies have assessed this relationship57,67,68 and only one has
investigated the association of vitamin D intake and OA57. This
study revealed that low levels of vitamin D intake are related to an
increased risk of OA progression but no correlation was made with
OA incidence. Interestingly, in this study, vitamin D intakemodestly
correlatedwith vitamin D serum levels. In addition, one other study
was found to evaluate the prevalence of vitamin D deﬁciency in
individuals with OA63. This study revealed a high prevalence of low
vitamin D status in patients with knee OA. The other studies
investigating the association between vitamin D serum level (25-
vitamin D) and joint structure parameters gave inconsistent data.
Two of them showed a relationship between vitamin D serum level
and OA parameters such as joint space narrowing and/or cartilage
volume in the knee or hip joint67,69. An other study did not show
any association between vitamin D serum level and joint space loss
in hip OA patients68. This difference could be explained by the fact
that the population of this study was younger than the population
of the other two. However no linear associationwas foundwhen OA
was assessed with a structural global score57,70. These studies
suggested a U-shaped relationship. Serum Vitamin D level is
reported to be predictive of knee OA, when measured by quartiles
with the lowest risk in the middle quartile70.
Polyphenols
Research on the effect of dietary polyphenols on human health
has developed considerably in the past 10 years. The results
strongly support the role of polyphenols in the prevention of
degenerative diseases. The anti-oxidant properties of polyphenols
have been widely studied, but it has become clear that the mech-
anisms of action go beyond the modulation of oxidative stress.
Some researchers have investigated the potential effect of some
polyphenols in OA. Only pine bark extract-Pycnogenol has been
tested in CTs.
Pine bark extract-Pycnogenol
Pycnogenol is a special standardized extract from the bark of
the French maritime pine (Pinus pinaster). This extract represents
a concentrate of polyphenols, containing several phenolic acids,
catechin, taxifolin and procyanidins with various biological and
clinical effects71. No-preclinical or in vitro data were found for
Pycnogenol and OA. However, the anti-oxidant and anti-inﬂam-
matory proﬁle of Pycnogenol and its inhibitory effect on MMPs
and iNOS are well documented in conditions other than OA72,73.
The symptom-modifying effect of Pycnogenol has been rela-
tively well documented in OA patients. The search retrieved four
CTs 71,73e75. They assessed the impact of Pycnogenol in patients
with knee OA in a medium term (3 months). These studies indicate
that the daily intake of 150 mg of Pycnogenol alleviated OA
symptoms. All studies showed that Pycnogenol was effective inreducing NSAIDs or COX-2 inhibitor medication, suggesting that
Pycnogenol could be used as an effective adjuvant treatment. Data
strongly support the pain-alleviating effect of Pycnogenol. Despite
some discordant results, physical function and stiffness seem to be
improved by intake of Pycnogenol in OA subjects. All these studies
are of good to very good quality (Farid et al, 200773 and Belcaro et al,
200875, score: 11; Cisar et al, 200871, score: 13).
Nobiletin
Nobiletin is a citrus polymethoxyﬂavone which was proven to
have pharmacological actions as anti-inﬂammatory, anti-tumor
proliferation and anti-tumor invasion and metastasis in vitro and in
vivo76. This product has been exclusively studied in vitro in synovial
ﬁbroblasts and in articular chondrocytes. Nobiletin was able to
inhibit the production of catabolic factors (MMP-3 and -9,
ADAMTS-4 and 5) and of mediators of inﬂammation (PGE2) in
rabbit and human synovial ﬁbroblasts76e78. Nobiletin was also
showed to activate the MMP inhibitor (TIMP-1)78. This inhibitory
potential was also demonstrated in rabbit articular chondrocytes77.
Nobiletin demonstrated a potential to inhibit cartilage degradation.
This chondroprotective potency should be further documented.
Curcumin
Curcumin (diferuloylmethane) is the major component of
turmeric, a yellow spice derived from the plant Curcuma longa and
a potent anti-oxidant. It has been extensively investigated due to its
anti-tumor, anti-oxidant and anti-inﬂammatory and analgesic
properties. We have recently reviewed the biological activities of
curcumin79. The anti-OA potential of curcumin has been widely
studied in vitro. Twelve studies were found. Theywere all carried out
in chondrocytes or on articular cartilage explants. Curcuminwas able
to downregulate catabolic and degradative effect observed in carti-
lage explants or chondrocytes stimulated with IL-1b, LPS or tumor
necrosis factor (TNF). Curcumin inhibited the production of MMP-3,
-9 and -1380e82 and restored type II collagen andGAG synthesis81e85.
Curcuminpositive effectonGAGreleasewasconﬁrmed86. Inaddition,
curcumin demonstrated potent anti-inﬂammatory properties by
inhibiting key inﬂammatory mediators (IL-6, IL-8, PGE2, NO) and
enzymes (COX-2 and iNOS)87e90 and anti-catabolic properties by
inhibitingMMP-3 synthesis89. Curcumin has also demonstrated anti-
apoptotic activity on chondrocytes83 and growth-inhibitory and pro-
apoptotic effects on synovial adherent cells, which are the main
source of inﬂammatory mediators and other mediators of cartilage
degradation, all of them playing key role in the pathogenesis of
arthritis91. This is important to note that one study has reported
a toxic effect of curcumin used at high dosage (50 mM) without any
beneﬁcial effect in cartilage matrix84. This study was performed in
a novel immortalized human OA chondrocytes model, which can
explain the discordance with previous studies.
No clinical data are available for the effect of curcumin in OA.
However, one study tested the clinical efﬁcacy of a herbomineral
formulation containing a component rich in curcumin in subjects
with OA in a randomized, double-blind, placebo-controlled, cross-
over study92. Positive results in pain management and mobility
were obtained in the treated group. Curcumin in OA is a current
research interest.
Genistein
Genistein is one of the several known isoﬂavones and is found in
soybeans and soy products. Genistein is considered as a phytoes-
trogen. Clinical observations have suggested a relationship
between OA and a changed estrogen metabolism in menopausal
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various menopausal symptoms93. The effect of phytoestrogens,
including genistein, has been studied on articular cartilage matrix
metabolism and inﬂammation. Nevertheless, the data for genistein
and OA are limited. The in vitro and preclinical data are not
consistent to support a beneﬁcial effect of genistein on articular
cartilage. Genistein does not affect cartilage metabolism93,94 but
could have an anti-inﬂammatory effect by suppressing COX-2 but
not NO production94. In addition, the consumption of an extract of
soy phytoestrogen in animal failed to modify cartilage metabolism
in ovariectomised monkey95. Additional experiments are needed to
clarify the potential beneﬁt of genistein in articular cartilage
metabolism.
Epigallocatechin-3-Gallate (EGCG)
EGCG is amajor component of the polyphenolic fraction of green
tea and exhibits anti-oxidant, anti-tumor and anti-mutagenic
activities. The in vitro effect of EGCG iswell documented.Most of the
availabledata onEGCGandOAcome fromexperimentsperformed in
vitro in human chondrocytes looking at the anti-inﬂammatoryeffect
of EGCG. Data suggest that EGCG exerts an anti-inﬂammatory effect
on OA chondrocytes by inhibiting the production of key inﬂamma-
tory mediators (NO, PGE2, COX-2 and iNOS)96e98. This anti-inﬂam-
matory effect has also been observed in osteoblasts by the inhibition
of IL-699 and synovial ﬁbroblasts by the inhibition of COX-2
expression and synthesis and by the inhibition of PGE2 and IL-8
secretion100. Additional anti-inﬂammatory and anti-catabolic
effects have been demonstrated for EGCG in human chondrocytes.
Indeed, EGCG can inhibit the TNF-a and MMP-13 production
induced by advanced glycation end products (AGEs) which are
responsible for cartilage mechanical properties loss101. This effect
could happen through the attenuation ofMAP kinase activation and
inhibition of nuclear factor kB (NF-kB) activation. This is supported
by the previous report of anti-catabolic activity and inhibitory effect
onNF-kBandAP-1 signalling102. Finally, this is of interest tonote that
the polyphenolic fraction of green tea can prevent the onset of
arthritis and the severity of the disease in mice collagen-induced
arthritis103. Complementary experiments are necessary in order to
conﬁrm the anti-inﬂammatory effect of EGCG on OA in vivo.
Resveratrol
Resveratrol is a stilbene that is naturally present at high
concentration in grape skin and red wine. It has signiﬁcant anti-
inﬂammatory and anti-oxidant properties which could be beneﬁ-
cial in OA104. Only in vitro studies were identiﬁed for this
compound. A total of ﬁve studies were performed in cartilage
explants and chondrocytes85,104e107. These studies indicated that
resveratrol can have beneﬁcial effects. It has demonstrated anti-
inﬂammatory and anti-apoptotic properties104,106. Resveratrol
inhibited catabolic factors as MMPs and pro-inﬂammatory media-
tors as PGE2 and COX-2, and stimulated the synthesis of matrix
components (PG, GAG, type II collagen)104,106,107. These effects could
prevent cartilage degradation. In addition, cartilage protection may
be achieved with intra-articular injection of resveratrol. This was
observed both in anterior cruciate ligament transaction OA model
and LPS-induced arthritis model in rabbit108,109. These preclinical
evaluations indicate an interesting potential of resveratrol in OA
but additional in vivo studies are needed.
Prodelphinidins
Prodelphinidins are a type of condensed tannins and are
composed of gallocatechin and epigallocathechin110. Only one invitro study has investigated the effect of prodelphinidins. This study
showed potential in vitro effects on human chondrocytes. Prodel-
phinidins seemed to increase PG and type II collagen and inhibited
PGE2 synthesis by acting on COX-2110. These data are in favor of
additional preclinical evaluations.
Quercetin
Quercetin is a plant-derived ﬂavonoid. Anti-inﬂammatory and
anti-oxidant properties have been suggested for this nutraceutical.
Only one in vitro study in human synovial cells has been identi-
ﬁed111. This study demonstrated potential anti-inﬂammatory effect
by the inhibition of TNF-a mediated-IL-8 and monocyte chemo-
attractant protein-1 (MCP-1) expression. This suggested a potential
anti-arthritic effect but further preclinical investigations are
needed especially in OA.
Ventol
Ventol is a phlorotannin-rich natural agent derived from Eck-
lonia cava with anti-oxidant and anti-inﬂammatory activities112.
One in vitro study on cartilage explants has shown the inhibition of
PG degradation after IL-1a stimulation. This should be further
studied to conﬁrm the anti-OA potential of this compound.
Discussion
OA is a debiliting chronic disease with a serious need of alter-
native treatments that could help patients to preserve their joint
function and therefore maintain a certain quality of life. We have
here summarized most of the published effects of some nutra-
ceuticals. Many results have been highlighted and the quality of the
studies addressed.
Globally, we can conclude to a lack of evidence for most of the
studied compounds. The review by Ameye and Chee6 has also
analyzed the available studies at that time for ASU, n-3 PUFAs and
CH. The same conclusions as ours were made, meaning that there
are no strong clinical data available. So, there is a need for addi-
tional preclinical studies and CTs of good quality. In addition, this is
important to note that the potencies demonstrated in preclinical
studies for most compounds are not concordant with their clinical
efﬁcacy. This could be explained by the doses used in vitro and in
animal models that are most of the time higher that the ones used
in CTs. An other explanation could come from the fact that
preclinical studies deal most of the time with early stages of the
disease whereas CTs involve patients at later stages. This can justify
the discordance between preclinical data and clinical and epide-
miological observations.
Many efforts have been carried out to ﬁnd a cure for OA. OA
management is a challenge for physicians and rheumatologists.
Many alternatives are now available but recommendations have to
be done. Nutraceuticals is one of these alternatives. They have great
potential in OA but there is a need of strongly substantiated data.
Many questions still remain to be addressed. Where should be
the line between food and drugs drawn? This issue is well illus-
trated by ASU mixture. ASU are considered as prescribed drugs in
France, but as food supplement in other countries. The prescribed
drug, Piascledine300, is now recommended for the treatment of
OA symptoms. These recommendations are based on strong clinical
evidence. However, in vitro studies have demonstrated that some of
the beneﬁcial effects of Piascledine300 were related to its
particular formulation resulting of a patented extraction process,
and were not observed with other formulation (personal commu-
nication). This extraction process is responsible for speciﬁc changes
in the unsaponiﬁable fractions of avocado and soybean that could
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ingredient has underwent some modiﬁcations that are related to
particular biological effects. Therefore, ASU should be chemically
analyzed before to be considered as a food supplement or a nutra-
ceutical. Nutraceutical is a broad term to qualify any product
derived from food source that provides extra health beneﬁts. This
deﬁnition fails to precise whether a modiﬁed product derived from
food source can be considered as a nutraceutical. The line between
a nutraceutical and a drug is thin. Other criterion that can help to
distinguish between a drug, food supplement, and nutraceuticals
are the oral dose administrated and the bioavailability. Food
supplement should be administrated at concentration found in the
normal diet. Bioavailability would be a great criterion to demon-
strate the potent efﬁcacy of a product. For example, the pharma-
cokinetic of curcumin has been studied113 and many parameters
that are opposed to curcumin efﬁcacy have been described. In
human, the serum concentrations of curcumin after an oral massive
dose of 4, 6 or 8 g/day reach 0.5, 0.6 and 1.8 mM respectively. These
concentrations are below the concentration showing a biological
activity in vitro. However, new formulation of curcumin114 has
enhanced cellular uptake, increased bioactivity in vitro and
improved bioavailability in vivo. This is in favor of a better efﬁcacy,
meaning that the anti-inﬂammatory and other potencies of cur-
cumin could be even more effective. Curcumin would become by
the way a potent anti-inﬂammatory agent. For this reason, a clinical
study has been initiated with complexed curcumin in patients with
knee OA. This complexed curcumin (Arantal) showed a 7000
times increased solubility. Can it be considered as a food supple-
ment any longer? This critical point can also be illustrated by
resveratrol. The pharmacokinetic of resveratrol can be modiﬁed by
the addition of glycosyl groups that improved its absorption115. This
process could be applied to other polyphenols to increase their
bioavailability.
Can nutraceuticals still be considered as food supplement when
used under drug formulation? These modiﬁcations should also be
controlled and regulated. Moreover, food nutrients can target
multiple pathways compared to monomodal mode of action of
drugs. For example, some natural anti-oxidant peptides have also
been identiﬁed in porcine CH116. CH has hypotensive potential117,118.
This is an additional advantage for the use of CH. Moreover, it has
recently been demonstrated that some nutraceuticals are even
more effective when used in combination. It has been shown for
EGCG and ASU119 and resveratrol and curcumin120. Safety and
toxicity of nutraceuticals added alone or in combination should also
be addressed, especially if bioavailability and biological activity are
increased. Pharmacokinetic of all these compounds should be
described and safety monitoring should be done.
For these reasons, the safety and effectiveness of these products
are under strict regulation in Europe. The problem is that the
criterion of evaluation for clinical studies are deﬁned as for phar-
maceutic standards and this penalizes foods in terms of effect size
and also of absence of acute effect. OA as a chronic disease has
a long time window for intervention and should beneﬁt from
functional food alternatives to pharmacological interventions to
improve subjects’ quality of life day after day.
We have also searched for the ongoing CTs with nutraceuticals.
They are all summarized on Table VIII and given an overview of the
current research interest on the selected ingredients. The number
of ongoing trials supports the growing interest to identify their role
in OA treatment. Two CTs are ongoing in order to evaluate the
efﬁcacy of vitamin D supplementation on pain, mobility and joint
structure in OA patients. Because of their high quality (long dura-
tion and strong study design) these results will be valuable for the
determination of the role that could play vitamin D supplementa-
tion in OA. More evidences are needed regarding the role that itcould play in the prevention of OA. Two CTs are ongoing on cur-
cumin to determine whether the consumption of a plant extract
with high curcumin content alleviates pain in subjects with OA.
Furthermore, one CT was just completed with CH. It was the ﬁrst
one interested in the structure-modifying effect of the studied
compound. The results are not yet available. Additional CTs should
assess the potential of nutraceuticals in a long-term use in OA and
should also be interested in their structure-modifying effect which
is the great challenge in seeking new OA treatment.
We have shown here that most of the studied compounds could
have beneﬁcial effects in the treatment of OA, even if we still need
more evidence. They could represent great alternatives for OA
management. We have only detailed here the information for a few
compounds but others can also represent great potential. Indeed,
other lipids, vitamins, minerals or plant extracts have also been
demonstrated to be effective in OA. Probiotics could also be
considered for the treatment of OA. Several studies have
highlighted the importance of intestinal ﬂora in inﬂammatory
auto-immune diseases, such as rheumatoid arthritis. Beneﬁcial
anti-inﬂammatory properties and modulatory effect of immune
response of probiotics on rheumatoid arthritis were demonstrated
in animals121e123. In addition, the consumption of lactobacilli con-
tained in a yogurt demonstrated the preventive and curative effects
on T-cell-dependent experimental arthritis by reducing the
intensity of inﬂammation and joint destruction in animals124. In the
same way, CTs have evaluated the effects of probiotics on the
activity and on the symptoms of rheumatoid arthritis125,126. The
positive ﬁndings of these studies suggested the need of comple-
mentary studies on the effects on probiotic bacteria in rheumatoid
arthritis. There is a lack of data on the effect of probiotics on OA in
the literature. The potential effect of probiotics on OA has not been
extensively studied but the data on their effect in arthritis suggest
that they could have a potential interest in OA.
Conclusion
We have gathered here all the studies and CTs about some
nutraceuticals. Some results are really promising and encouraging.
The main concern remains the quality of studies. There is a need of
serious and well designed studies that could answer most of the
questions regarding the safety and efﬁcacy of such compounds. This
could help their recommendation for OA treatment.
Many studies have been carried out in order to highlight the
potency of several nutraceuticals for the treatment of OA. Nutra-
ceuticals offer a large variety of products with a wide range of
effects. They open new and large horizons for the treatment of
chronic disease as OA. Clinical endpoints for foods should be
reconsidered. Further investigations are needed but nutraceuticals
are not negligible for OA management. They should be considered
as potent adjuvant treatments with NSAIDs for example. Early
markers development would also enable to build prevention
strategies for food, in absence of cure treatment for OA.
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